Small Cell Lung Cancer (SCLC)

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup, with a chemotherapy-free interval of 90 or more days.

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Results from a phase 2 study showed a median OS of 10.2 months in all patients with small cell lung cancer who received stereotactic radiation therapy.

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.

The addition of angiogenesis inhibition to immunochemotherapy for untreated extensive-stage small cell lung cancer did not significantly increase toxicity.

Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early antitumor activity of CID-078 in advanced solid tumors.

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.

The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Safety and efficacy were noted with LB2102 for patients with small cell lung cancer and large cell neuroendocrine carcinoma.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild to moderate severity.

The safety profile of camrelizumab plus apatinib and chemotherapy in a phase 1 study aligns with prior reports of each agent.

The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

No new safety signals were observed with bevacizumab, atezolizumab, carboplatin, and etoposide in extensive-stage small cell lung cancer.

Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.

Data may support anlotinib/benmelstobart plus chemotherapy as a preferable frontline treatment option in extensive-stage small cell lung cancer.

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.